Extended Longevity, Inc. – Trademark Portfolio
Entity Type: 03
Extended Longevity, Inc. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 10 trademarks are registered and 2 are pending. Notable registered marks include EMOPHIX, EPIVERSE, THYVOLVE, BLUECOSIG, and CNIDIUM M. The owner is based in Kula, HI.
3361 Omaopio Road,
3361 Omaopio Rd Unit B
Kula, HI 96790
Showing of trademarks Trademarks
Trademark Classifications
Extended Longevity, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Extended Longevity, Inc. have?
Extended Longevity, Inc. has 18 U.S. trademarks filed with the USPTO. Of these, 10 registered, 2 pending, 6 abandoned.
What trademark classes does Extended Longevity, Inc. file in?
Extended Longevity, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Extended Longevity, Inc.'s most well-known trademarks?
Extended Longevity, Inc.'s registered trademark portfolio includes well-known marks such as EMOPHIX, EPIVERSE, THYVOLVE, BLUECOSIG, and CNIDIUM M. These are among 10 currently registered trademarks in the portfolio.
What is Extended Longevity, Inc.'s trademark registration success rate?
Extended Longevity, Inc. has a 63% trademark registration rate, with 10 out of 16 resolved applications resulting in successful registration. Currently, 2 applications are pending review.